"Based on the available data, and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The mRNA molecule eventually breaks down in the body. The Cleveland Clinic reports that the risks of mRNA vaccines include pain or swelling at the injection site, fever, fatigue, headaches, muscle ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization ...

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...